Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
Fig 14
Multicellular tumour spheroids (MCTSs) A and B prior to treatment commencing.
The MCTSs are visualised in both opaque and transparent formats. Hypoxic activator cells are shown in green and normoxic bystander cells are shown in blue. Activator and bystander cells are manually set so that MCTSs A and B contain the same number of activator and bystander cells before treatment commences.